Telomere Length Abnormalities Linked to Lymphoma Development

Early detection and long-term monitoring remain difficult, particularly for families with inherited cancer risk. Researchers are working to better understand how aging immune cells contribute to cancer development. New findings suggest that unusually long telomeres—the protective caps at the ends of chromosomes—linked to inherited genetic changes may increase lymphoma risk and offer insight into how the disease develops.

Researchers at the Johns Hopkins Kimmel Cancer Center and the Telomere Clinic at Johns Hopkins identified a genetic syndrome in which inherited loss-of-function variants in the POT1 gene maintain unusually long telomeres in immune cells. POT1 normally constrains telomere length, but when one gene copy is inactivated, telomeres become excessively long. In lymphocytes, this blunts the expected age-related telomere attrition and can enable survival of clones that accumulate cancer-associated mutations.

In an analysis of cancer histories and biospecimens from 51 individuals across 24 families carrying POT1 variants, hematologic malignancies and thyroid cancer were the most common diagnoses after melanoma. Three-quarters of the blood cancers arose from lymphocytes. Rarer, slow-growing myeloid neoplasms were also observed, sometimes occurring alongside lymphoma in the same individual.

To test generalizability, the team evaluated 210 adults with POT1 variants in the UK Biobank, identifying an eightfold higher risk of lymphoma, with 45% developing a lymphoid cancer by age 80. Among carriers without a lymphoma diagnosis, early lymphocyte clonality was detectable; after age 60, nearly all had expanded lymphocyte clones, and most harbored mutations commonly associated with lymphoma. Sixty percent exhibited ultra-long telomeres within the top 1% of the population, while others showed shorter lengths consistent with clonal expansion.

Telomerase activity is typically tightly controlled, but in lymphocytes lacking normal POT1 function, regulation appears disrupted, providing opportunities for further elongation as immune cells divide. The study, published in Blood, suggests a mechanism by which extended cellular longevity confers lymphoma susceptibility and may explain why some individuals develop multiple malignancies, including melanoma. 

The authors also note that telomere shortening with aging may serve a protective role by pruning damaged cells. With no established screening protocols for lymphoma, optimal surveillance for POT1 carriers remains uncertain and ranges from careful clinical monitoring to more proactive approaches pending further research.

“Our findings point to a new mechanism of lymphoma susceptibility that is linked to extended cellular longevity,” said Mary Armanios, M.D., professor of oncology and genetic medicine and director of the Telomere Clinic at Johns Hopkins. “In this setting, lymphocytes retain a kind of youthfulness that allows cancer-associated mutations to persist and expand over time.”

“Our data suggest that, for now, telomere length clinical testing should be reserved for individuals with variants in the gene that have unclear significance,” said Armanios.

Related Links
Johns Hopkins Kimmel Cancer Center
Telomere Clinic at Johns Hopkins